Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.709
-$0.0449-5.96%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.38% | -3.09% | 11.95% | 66.47% | 50.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.04% | -17.91% | 10.89% | 45.66% | 39.94% |
| Operating Income | 22.04% | 17.91% | -10.89% | -45.66% | -39.94% |
| Income Before Tax | 23.81% | 21.26% | -5.50% | -43.61% | -38.96% |
| Income Tax Expenses | 15.38% | -65.89% | 13.20% | 5.45% | -18.75% |
| Earnings from Continuing Operations | 23.79% | 21.29% | -5.51% | -43.59% | -38.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.79% | 21.29% | -5.51% | -43.59% | -38.92% |
| EBIT | 22.04% | 17.91% | -10.89% | -45.66% | -39.94% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 44.75% | 41.23% | 15.27% | -19.29% | -16.74% |
| Normalized Basic EPS | 44.76% | 41.20% | 15.26% | -19.33% | -16.77% |
| EPS Diluted | 44.75% | 41.23% | 15.27% | -19.29% | -16.74% |
| Normalized Diluted EPS | 44.76% | 41.20% | 15.26% | -19.33% | -16.77% |
| Average Basic Shares Outstanding | 39.35% | 35.33% | 30.35% | 26.73% | 21.87% |
| Average Diluted Shares Outstanding | 39.35% | 35.33% | 30.35% | 26.73% | 21.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |